Insulet Corporation (PODD)

NASDAQ: PODD · IEX Real-Time Price · USD
154.67
-1.03 (-0.66%)
Sep 25, 2023, 4:00 PM EDT - Market closed
-0.66%
Market Cap 10.80B
Revenue (ttm) 1.47B
Net Income (ttm) 62.90M
Shares Out 69.82M
EPS (ttm) 0.90
PE Ratio 171.86
Forward PE 79.84
Dividend n/a
Ex-Dividend Date n/a
Volume 33
Open 155.01
Previous Close 155.70
Day's Range 154.11 - 157.16
52-Week Range 154.11 - 335.91
Beta 0.81
Analysts Buy
Price Target 287.13 (+85.64%)
Earnings Date Nov 2, 2023

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorpo... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date May 15, 2007
Employees 2,600
Stock Exchange NASDAQ
Ticker Symbol PODD
Full Company Profile

Financial Performance

In 2022, Insulet's revenue was $1.31 billion, an increase of 18.79% compared to the previous year's $1.10 billion. Earnings were $4.60 million, a decrease of -72.62%.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for PODD stock is "Buy." The 12-month stock price forecast is $287.13, which is an increase of 85.64% from the latest price.

Price Target
$287.13
(85.64% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Will Insulet (PODD) Stock Recover To Its Pre-Inflation Shock Highs Of $300?

Returning to the pre-inflation shock level of $318 means that PODD stock will have to gain more than 100% from here.

22 minutes ago - Forbes

Wall Street analysts expect the S&P 500 to rise 19% over the next 12 months. Here are their 10 favorite stocks.

Outside of a handful of highflying technology stocks, U.S. stocks have been practically flat in 2023, but on Wall Street, some analysts remain as bullish as ever.

44 minutes ago - Market Watch

These 20 growth stocks are worth considering on a pullback, says Citi

Citi has released a list of 20 large-cap growth stocks that it says present opportunities in the event of a pullback.

18 hours ago - Market Watch

Medtech Makers Are the Real Losers From Obesity Drugs

Shares of companies that treat everything from Type 2 diabetes to sleep apnea have been sinking since new weight-loss medications skyrocketed.

Other symbols: DXCMINSPMDGLRMDTNDM
5 days ago - Barrons

Insulet shares slump on concerns of sales hit from new diabetes drugs

Insulin pumps maker Insulet Corp said on Thursday a new generation of diabetes drugs, known as GLP-1s, could delay the time that diabetes patients become dependent on insulin, sending its shares down ...

18 days ago - Reuters

Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System in Germany

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced th...

4 weeks ago - Business Wire

Insulet to Present at Upcoming Investor Conferences

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management ...

4 weeks ago - Business Wire

Insulet lifts sales growth forecast on strong demand for insulin pumps

Insulet Corp on Tuesday raised its annual revenue growth forecast and beat second-quarter profit and revenue estimates, on strong demand for its tubeless insulin pumps that are more convenient to use ...

6 weeks ago - Reuters

Insulet Reports Second Quarter 2023 Revenue Increase of 32% Year-Over-Year (32% Constant Currency1)

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced f...

6 weeks ago - Business Wire

Healthcare creating more opportunities for tech investors, says Harris Financial's Jamie Cox

Jamie Cox, Harris Financial Group managing partner, joins 'The Exchange' to discuss investment opportunities in medical devices, the intersection of healthcare and technology, and top picks in the med...

Other symbols: DXCM
2 months ago - CNBC Television

Insulet to Announce Second Quarter 2023 Financial Results on August 8, 2023

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced p...

2 months ago - Business Wire

These stocks could be the next Magnificent Seven market leaders, says Goldman Sachs

“Can tech keep up the pace?” is a burning question for many with regards to a sector that helped drive the S&P 500 SPX, +0.12% to its best first half since 2019.

3 months ago - Market Watch

Insulet Celebrates One Year of Omnipod® 5 at the American Diabetes Association 83rd Scientific Sessions

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced an...

3 months ago - Business Wire

Insulet Announces Omnipod® 5 Automated Insulin Delivery System is Now Available in the United Kingdom

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...

3 months ago - Business Wire

Insulet Announces New Organizational Structure to Drive Further Growth

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...

5 months ago - Business Wire

Insulet Reports First Quarter 2023 Revenue Increase of 21% Year-Over-Year (23% Constant Currency1)

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced f...

5 months ago - Business Wire

Insulet Publishes 2022 Sustainability Report Focused on Innovating for the Future and Preserving the Environment

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today released it...

5 months ago - Business Wire

Insulet Announces FDA Clearance of Omnipod GO™, a First-of-its-Kind Basal-Only Insulin Pod, Further Simplifying Life for People with Type 2 Diabetes

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...

5 months ago - Business Wire

Insulet to Announce First Quarter 2023 Financial Results on May 4, 2023

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced p...

6 months ago - Business Wire

Silicon Valley Bank out of S&P 500 index; Insulet selected to replace it

S&P Indices said late Friday that Insulet Corp. PODD, -0.97% will replace Silicon Valley Bank parent SVB Financial Group SIVB, -60.41% in the S&P 500 index SPX, -1.45% at the open on Wednesday. The ba...

Other symbols: SIVB
7 months ago - Market Watch

CORRECTING and REPLACING Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (24% constant currency)

ACTON, Mass.--(BUSINESS WIRE)--Please replace the release issued February 23, 2023, with the following corrected version due to multiple revisions.

7 months ago - Business Wire

CORRECTING and REPLACING Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (23% constant currency)

ACTON, Mass.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions.

7 months ago - Business Wire

Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (23% constant currency)

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced f...

7 months ago - Business Wire

Highly Anticipated Omnipod® 5 Real-World Evidence to be Presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...

7 months ago - Business Wire

Insulet Acquires Assets of Automated Glucose Control LLC (AGC)

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...

8 months ago - Business Wire